Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (925) Arrow Down
Filter Results: (925) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (925)
    • People  (2)
    • News  (70)
    • Research  (778)
    • Events  (1)
    • Multimedia  (2)
  • Faculty Publications  (667)

Show Results For

  • All HBS Web  (925)
    • People  (2)
    • News  (70)
    • Research  (778)
    • Events  (1)
    • Multimedia  (2)
  • Faculty Publications  (667)
← Page 21 of 925 Results →
  • 30 Oct 2007
  • First Look

First Look: October 30, 2007

Changing Context of Pharmaceutical Risk Mitigation Author:Arthur A. Daemmrich Periodical:Pharmacy in History 49, no. 2 (2007): 61-75 Abstract In the wake of Vioxx, Avandia, and other recent prominent cases of drugs found to cause side... View Details
Keywords: Sean Silverthorne
  • 01 Dec 2019
  • News

Remix

community after their respective accusations against Clarence Thomas and Mike Tyson. It’s one of the factors that helps explain why women of color report sexual assault at rates far below that of white women and a major force behind Dixon’s decision to leave the View Details
Keywords: Jen McFarland Flint; photographed by Chris Sorensen; #MeToo; DefJam; Arts, Entertainment
  • December 2019
  • Case

The Business of Pain: Johnson & Johnson and the Promise of Opioids

By: Erik Snowberg, Trevor Fetter and Amy W. Schulman
This case is designed to provide an engrossing overview of stakeholder capitalism through a vigorous discussion of the conflicts that can arise when trying to serve multiple stakeholders. In 2007, Johnson & Johnson’s (J&J) subsidiary Janssen has to decide whether or... View Details
Keywords: Opioids; Addiction; Stakeholder Capitalism; Business and Stakeholder Relations; Product Launch; Decision Making; Ethics; Social Issues; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Snowberg, Erik, Trevor Fetter, and Amy W. Schulman. "The Business of Pain: Johnson & Johnson and the Promise of Opioids." Harvard Business School Case 720-420, December 2019.
  • 01 Sep 2007
  • News

Alfred D. Chandler Jr. Remembered

Matsushita. That volume was followed in 2005 by Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries. “Such science-based View Details
  • February 2024
  • Case

Compass Pathways: Pioneering Psychedelic Treatment

By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no... View Details
Keywords: Commercialization; Corporate Strategy; Competitive Strategy; Product Launch; Health Testing and Trials; Research and Development; Laws and Statutes; Pharmaceutical Industry; Europe; United States; United Kingdom
Citation
Educators
Purchase
Related
Zuzul, Tiona, Kisha Lashley, and Gamze Yucaoglu. "Compass Pathways: Pioneering Psychedelic Treatment." Harvard Business School Case 724-412, February 2024.
  • February 2010 (Revised September 2011)
  • Case

Roche's Acquisition of Genentech

By: Carliss Y. Baldwin, Bo Becker and Vincent Marie Dessain
Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and... View Details
Keywords: Mergers and Acquisitions; Business Subsidiaries; Negotiation Offer; Organizational Culture; Corporate Strategy; Biotechnology Industry; Biotechnology Industry; Switzerland
Citation
Educators
Purchase
Related
Baldwin, Carliss Y., Bo Becker, and Vincent Marie Dessain. "Roche's Acquisition of Genentech." Harvard Business School Case 210-040, February 2010. (Revised September 2011.)
  • October 2022
  • Case

Cost Plus Drugs

By: Alexander MacKay and James Barnett
In September 2022, Mark Cuban Cost Plus Drugs Company CEO Alex Oshmyansky considered the future of the company. Cost Plus Drugs was a retailer for more than 340 generic oral medications, selling their drugs at significantly lower prices than typical pharmacies.... View Details
Keywords: Business Ventures; Decision Making; Entrepreneurship; Ethics; Health; Markets; Social Enterprise; Society; Strategy; Health Care and Treatment; Business Divisions; Factories, Labs, and Plants; Health Industry; Health Industry; United States; Texas
Citation
Educators
Purchase
Related
MacKay, Alexander, and James Barnett. "Cost Plus Drugs." Harvard Business School Case 723-362, October 2022.
  • Web

Request more information | HBS Courses | HBS Online

Aerospace/Defense Agriculture Auto Communications E-Commerce E-Education Energy Entertainment Financial Services Food/Beverage Health/Medical Hospitality Insurance Manufacturing Non-Profit Pharmaceuticals Professional Services Retail... View Details
  • March 2023 (Revised March 2023)
  • Case

Roche: Innovation and Access to Healthcare

By: George Serafeim, Susanna Gallani and Benjamin Maletta
In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that had... View Details
Keywords: ESG (Environmental, Social, Governance) Performance; Sustainable Finance; Growth Strategy And Execution; Sustainability Targets; Impact Evaluation; Healthcare Access; Healthcare Innovation; Healthcare Systems; Healthcare Operations; Finance; Strategy; Health Testing and Trials; Health Care and Treatment; Growth Management; Measurement and Metrics; Innovation Strategy; Corporate Social Responsibility and Impact; Health Industry; Health Industry; Switzerland; North America; Europe; Asia; Latin America; Africa
Citation
Educators
Purchase
Related
Serafeim, George, Susanna Gallani, and Benjamin Maletta. "Roche: Innovation and Access to Healthcare." Harvard Business School Case 123-075, March 2023. (Revised March 2023.)
  • July 2001 (Revised August 2005)
  • Case

Medicines Company, The

By: John T. Gourville
It is early 2001 and the Medicines Co. just received FDA approval to market Angiomax, a blood thinner to be used during angioplasties and heart procedures. It is intended to be a better alternative to Heparin, an 80-year-old drug that costs less then $10 per dose. The... View Details
Keywords: Business Model; Change Management; Decision Choices and Conditions; Cost Management; Price; Product Marketing; Product Launch; Product Development; Risk and Uncertainty; Health Industry; Health Industry
Citation
Educators
Purchase
Related
Gourville, John T. "Medicines Company, The." Harvard Business School Case 502-006, July 2001. (Revised August 2005.)
  • September 1990 (Revised November 1991)
  • Case

Merck & Co., Inc. (B)

In late 1986, Merck revised its performance review and pay practices. The most important change was a shift from an absolute rating system to a forced-distribution system in which managers are forced to adhere to a given distribution of performance ratings. Other major... View Details
Keywords: Performance Evaluation; Compensation and Benefits; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Murphy, Kevin J. "Merck & Co., Inc. (B)." Harvard Business School Case 491-006, September 1990. (Revised November 1991.)
  • 27 May 2009
  • First Look

First Look: May 27, 2009

industry and services. Although each Mubadala investment is supposed to earn large returns, the strategy balances financial against "strategic" returns. ADIA and Mubadala are the institutional architecture to manage the wealth... View Details
Keywords: Martha Lagace
  • 03 Feb 2015
  • First Look

First Look: February 3

field and other business fields complements the contributions from industrial organization economics (IO). These business fields also offer theoretical and empirical challenges to the IO paradigm, which dominates antitrust analysis. The... View Details
Keywords: Sean Silverthorne
  • 15 Jan 2013
  • First Look

First Look: January 15

circumscribe citizen-employees, and they engage in production and trade. But individual corporations are no longer adequate to serve as the primary unit of analysis. Over the years, systems of distributed innovation-so-called business ecosystems-have become... View Details
Keywords: Sean Silverthorne
  • September 2010 (Revised July 2013)
  • Case

Alnylam Pharmaceuticals: Building Value from the IP Estate

By: Willy C. Shih and Sen Chai
The learning objective of this case is to help students recognize the interplay between intellectual property (IP) rights and corporate strategy. We do this by examining what is a fairly atypical circumstance today in which a single firm is able to secure what it... View Details
Keywords: Patents; Lawsuits and Litigation; Rights; Competitive Strategy; Corporate Strategy; Biotechnology Industry; Biotechnology Industry; United States
Citation
Educators
Purchase
Related
Shih, Willy C., and Sen Chai. "Alnylam Pharmaceuticals: Building Value from the IP Estate." Harvard Business School Case 611-009, September 2010. (Revised July 2013.)
  • November 2016
  • Case

Transformation at Eli Lilly & Co. (A)

By: William R. Kerr and Alexis Brownell
Faced with the imminent loss of 40% of its revenues due to patent expirations, pharma giant Eli Lilly sets out on a dramatic transformation process in 2009. The case considers how Lilly restructured the organization into business areas to aid better decision-making,... View Details
Keywords: Eli Lilly; Restructuring; R&D; Transformation; Organizational Change and Adaptation; Organizational Structure; Pharmaceutical Industry; Indianapolis
Citation
Educators
Purchase
Related
Kerr, William R., and Alexis Brownell. "Transformation at Eli Lilly & Co. (A)." Harvard Business School Case 817-070, November 2016.
  • October 2000 (Revised March 2003)
  • Case

Merck & Company: Evaluating a Drug Licensing Opportunity

By: Richard S. Ruback and David B Krieger
This explores the valuation of an opportunity to license a compound before it enters clinical trials. Describes Merck's decision tree evaluation process is presented. Information required to evaluate a specific licensing opportunity is provided, including the costs of... View Details
Keywords: Decision Making; Cost vs Benefits; Opportunities; Valuation; Outcome or Result; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Ruback, Richard S., and David B Krieger. "Merck & Company: Evaluating a Drug Licensing Opportunity." Harvard Business School Case 201-023, October 2000. (Revised March 2003.)
  • Web

Research - Health Care

UAE for fibroids or adenomyosis were captured from electronic health record timestamps and... May 2024 Article Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms By: Caroline Marra... View Details
  • May 1998 (Revised May 1999)
  • Case

Biopure Corp.

By: John T. Gourville
It is early 1998 and Biopure Corp., a small biopharmaceutical firm with no sales revenues in its ten-year history, has just received government approval to release Oxyglobin, a revolutionary new "blood substitute" designed to replace the need for donated animal blood... View Details
Keywords: Segmentation; Marketing Strategy; Engineering; Budgets and Budgeting; Sales; Transformation; Markets; Debates; Product Launch; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Gourville, John T. "Biopure Corp." Harvard Business School Case 598-150, May 1998. (Revised May 1999.)
  • June 2004 (Revised June 2006)
  • Supplement

Vertex Pharmaceuticals: R&D Portfolio Management (A)

By: Gary P. Pisano, Lee Fleming and Eli Strick
Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will... View Details
Keywords: Research and Development; Investment Portfolio; Pharmaceutical Industry
Citation
Purchase
Related
Pisano, Gary P., Lee Fleming, and Eli Strick. "Vertex Pharmaceuticals: R&D Portfolio Management (A)." Harvard Business School Supplement 604-101, June 2004. (Revised June 2006.)
  • ←
  • 21
  • 22
  • …
  • 46
  • 47
  • →
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.